Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00153946
Status:
COMPLETED
Last Update Posted:
2008-05-14
First Post:
2005-09-08
Brief Title:
Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke
Sponsor:
Combination Therapy for Acute Ischemic Stroke Study Group
Organization:
Combination Therapy for Acute Ischemic Stroke Study Group
Study Overview
Official Title:
Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EAST
Brief Summary:
Edaravone a free radical scavenger is a novel neuroprotective agent and argatroban is a selective thrombin inhibitor Both the drugs were approved by the Japanese Government and have frequently been used for the treatment of acute brain infarction in Japan The effect of combination therapy of these drugs however has not yet been elucidated This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None